Full Text View
Tabular View
No Study Results Posted
Related Studies
Human Anti-Tac (Daclizumab) to Treat JIA-associated Uveitis
This study has been completed.
Study NCT00130637   Information provided by National Institutes of Health Clinical Center (CC)
First Received: August 12, 2005   Last Updated: October 31, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Anterior Uveitis
Arthritis, Juvenile Idiopathic
Daclizumab
Iritis
Immunosuppression
Additional conditions recognized in this trial
Arthritis
Arthritis, Juvenile Rheumatoid
Uveitis
Uveitis, Anterior
More general conditions related to this trial
Arthritis, Rheumatoid
Autoimmune Diseases
Connective Tissue Diseases
Eye Diseases
Immune System Diseases
Iris Diseases
Joint Diseases
Musculoskeletal Diseases
Panuveitis
Rheumatic Diseases
Uveal Diseases
Interventions listed in this trial
HAT, Daclizumab
Additional drug interventions recognized in this trial
Daclizumab
More general drug interventions related to this trial
Immunologic Factors
Immunosuppressive Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
National Eye Institute (NEI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services